Physician
X-Gene INC
X-Gene INC was paid $1.65M by Medicaid between Jul 2019 and Dec 2024, across 26 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 42% of everything it billed.
33Billing provider infoX-GENE INC
SPARKS GLENCOE, MD 21152
SPARKS GLENCOE, MD 21152
33aNPI1770973646assigned 01/30/2015
33bProvider typeMolecular Genetic Pathology (Pathology) Physician
28Total paid$1.65M
24GClaims43,068
24DCodes billed26
24AFirst – last monthJul 2019 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 3,454 | $83K | |
| 2020 | 10,268 | $423K | |
| 2021 | 8,089 | $320K | |
| 2022 | 13,470 | $440K | |
| 2023 | 4,551 | $221K | |
| 2024incomplete | 3,236 | $159K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 42% | 14,030 | 6,424 | $690K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 21% | 2,361 | 1,904 | $352K |
| 87481 | 7.1% | 2,117 | 1,724 | $117K | |
| 87551 | 6.2% | 2,056 | 1,705 | $102K | |
| 87530 | 5.4% | 1,976 | 1,633 | $90K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.8% | 2,411 | 1,972 | $47K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.7% | 2,368 | 1,975 | $44K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 2.6% | 2,328 | 1,940 | $42K |
| 87653 | 2.1% | 2,130 | 1,760 | $34K | |
| 87109 | 1.9% | 1,975 | 1,645 | $32K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.6% | 5,102 | 2,180 | $27K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.0% | 136 | 89 | $17K |
14 more codes
| 87640 | <1% | 578 | $10K | |
| 87500 | <1% | 406 | $7K | |
| 87529 | <1% | 144 | $6K | |
| 87641 | <1% | 318 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 142 | $5K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 134 | $4K |
| 87185 | <1% | 408 | $3K | |
| 87511 | <1% | 173 | $3K | |
| 80202 | <1% | 381 | $3K | |
| 87177 | <1% | 403 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 406 | $2K |
| 87581 | <1% | 130 | $1K | |
| 87081 | <1% | 403 | $972.26 | |
| 87541 | <1% | 52 | $871.36 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWANG, XIAO BING (OWNER)